CLAIMS

~~1. A 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salt selected from ethanesulfonate, fumarate, hydrochloride, malate, maleate, malonate and methanesulfonate.~~

~~21~~. ~~The 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salt according to claim 1 wherein the salt is the hydrochloride~~ Hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine.

~~32~~. A process for the preparation of the hydrochloride salt of claim ~~21~~, comprising:

a) mixing 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine and a solution containing hydrochloric acid, and

b) isolating the resulting hydrochloride salt.

~~43~~. A pharmaceutical composition comprising the hydrochloride salt of claim ~~21~~.

~~54~~. The hydrochloride salt of claim ~~21~~ for use as medicament.

~~65~~. The hydrochloride salt of claim ~~21~~ for use in the treatment and/or prophylaxis of a sigma receptor mediated disease or condition.

~~76~~. The hydrochloride salt of claim ~~21~~ for use in the treatment and/or prophylaxis of a disease selected from the group consisting of diarrhoea; lipoprotein disorders; migraine; obesity; arthritis; hypertension; arrhythmia; ulcer; learning, memory and attention deficits; cognition disorders; neurodegenerative diseases; demyelinating diseases; addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive diskinesia; ischemic stroke; epilepsy; stroke; stress; cancer; psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation; or autoimmune diseases.